The NEJ009 study reported that patients with EGFR-mutant NSCLC could gain an OS benefit from combined treatment with chemotherapy and EGFR–TKIs compared to EGFR–TKIs alone [39]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.